both products are still used a lot in AU. and of course in 2nd & 3rd world a lot more. As for ACR going bust...........? I have no idea. IF we achieve cashflow positive in 4 months or very close to it ......... ACR should prevail long term. In my mind I'm thinking ( a very very speculative guess on my part) that most generics will earn for ACR anywhere from US$ 1/2 a cent to, if lucky , 2 cents a share. there's some 282 odd million outstanding shares. Once we have the Testosterone figures, which should earn more than say Elma Cream, that will be a benchmark of sorts. we will be able to look at total US market sales of a product(s)....... number of players in each segment.... and see overall what sort of market % were getting. So if we start averaging (example only) 2-3% on each product that may end up being a very rough guide to how each new launched product goes.
ACR Price at posting:
5.9¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)